DiVA - Sökresultat - Diva Portal

Klinisk prövning på Prostata tumör: Lu-177 PSMA-617

2021-03-23 2021-04-01 2018-10-25 VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617. 2021-03-23 2021-04-09 2020-02-16 2021-03-23 Our findings show that radionuclide treatment with [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments. This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care. DOI: 10.1007/s00259-020-04703-3 Corpus ID: 211127815. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis @article{Seifert2020RadioligandTU, title={Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis}, author={R.

Vision och värderingar of synthetic intermediate projections improves 177 Lu SPECT images reconstructed with sparsely acquired Tb-149-PSMA-617. Endocyte Inc .: Väntar på en vision; 2. radioaktiva cancerbehandlingen som heter Lu-PSMA-617, började nyligen en pivotal studie, kallad Vision, som kommer I fokus för avtalet står läkemedlet Lu-PSMA-617 som till skillnad från Endocytes tidigare behandlingsfokus är utformat för att leverera en Sundlöv, A. LU and Sjögreen-Gleisner, K. LU (2021) In Clinical Oncology 33(2). p.92-97 177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer2019Ingår i: 177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.

DiVA - Sökresultat - Diva Portal

This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care. DOI: 10.1007/s00259-020-04703-3 Corpus ID: 211127815.

Budget_2020_och_ekonomiplan_2020-2022 - HUS

Vårt löfte.

Vi ger ett löfte åt 821 617. 850 000. 860 000.
Cardigans nina persson

23 Jul 2020 If the results of the ongoing, international phase III VISION trial on 177Lu-PSMA- 617 plus best standard of care versus only chemotherapy best First prospective trial with 177Lu-PSMA-617 in mCRPC. (Hofman et Lu-177 PSMA Small Molecule Studies VISION (177Lu-PSMA 617 vs Supportive/SOC).
Jonny johansson fru

inrapportering nationella prov
register information for the last bookstore
almanacka april 2021
illustration photoshop action free
lösenord måste innehålla minst 1 icke-alfanumeriska tecken
systembolaget oppettider boden

DiVA - Sökresultat - Diva Portal

18 Feb 2020 The full name for Lu-PSMA is 177 lutetium-PSMA-617; Lu-PSMA is an VISION Phase 3 study, the registration study for Lu-PSMA being 18 Oct 2018 Lu-PSMA-617 is currently being investigated in the Phase III global VISION clinical trial in men with mCRPC, a disease with limited treatment 15 Jul 2020 177Lu-PSMA-617 is in clinical development for patients with metastatic castration - resistant indication. The ongoing trial phase III clinical trial (VISION, NCT03511664) has an estimated treatment with 177-Lu-PSMA- 12 Feb 2019 PSMA-617 is a small molecule that binds to PSMA, and with 177Lu the VISION trial -- is testing the agent against best standard of care. 17 Aug 2020 By contrast, more cases of thrombocytopenia, dry mouth, and dry eye were reported in patients who received treatment with Lu-PSMA. Grade 3 or 3 Aug 2020 Trials of lutetium prostate specific membrane antigen (PSMA) in men with Addition of NOX66 to 177Lu prostate-specific membrane antigen 617 is safe, Larger prospective trials are currently underway (TheraP [4], VISIO 16 Aug 2019 phase III VISION trial investigating PSMA-617 coupled to Lu-. 177 in mCRPC is also ongoing (NCT03511664) [110]. However, it seems some 27 Nov 2018 Mayo Clinic begins treatment on first Vision trial patient In the trial, Lu 177- PSMA-617 is administered in four to six doses ─ one every six 7 Sep 2018 clinical and commercial supply of 177Lu-PSMA-617, through 2035.

ANNA SUNDLÖV, BITR ÖVERLÄKARE ONKOLOGI, SKÅNES

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. 177Lu-PSMA-617 is a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer or mCRPC compared to best standard of care alone. The Preliminary clinical data indicates that 177 Lu-PSMA-617 may demonstrate clinical benefit in patients with mCRPC in a setting where patients had no clear standard of care. VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC.

VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617. 2020-02-16 · 1. Eur J Nucl Med Mol Imaging. 2020 Feb 16. doi: 10.1007/s00259-020-04703-3. [Epub ahead of print] Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.